FDA is in general agreement with the design of two proposed randomized clinical trials of AB-SA01, for Staphylococcus aureus bacteremia and prosthetic joint infections, and no additional preclinical or clinical data are required to proceed with both trials AmpliPhi expects to initiate one of these clinical trials in early 2019 AmpliPhi continues to investigate if […]
21 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have now been treated with AB-SA01 (targeting S. aureus) or AB-PA01 (targeting P. aeruginosa) under AmpliPhi’s expanded access program Over 1,000 doses of bacteriophage product candidates, AB-SA01 or AB-PA01, have been administered as part of the expanded access program since mid-2017 […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-09-17 04:04:532019-02-13 12:18:47AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program
10 September 2018 – Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures. Through the […]
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Brighton, United Kingdom – 6 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), announces that Sir Nigel Rudd is stepping down as Chairman and a member of […]
23 Aug 2018 San Mateo, CA – August 23, 2018: Adherium (ASX:ADR) a digital health platform focused on improving medication adherence and patient outcomes, and Vitalus Health, a leading provider of comprehensive health and wellness solutions that focus on pulmonary disease management, today announced a broadened strategic program encompassing Adherium’s Hailie™ solution. With the expansion of its […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-08-23 02:46:062018-09-04 02:47:38Adherium and Vitalus Health Launch Commercial Program to Support Patients with Asthma and COPD
Valencia, Calif., USA, and Melbourne, Australia, 23 August 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced the successful completion of multiple production runs for the RECELL Device® within its newly acquired manufacturing facility in Ventura, California. Effective July 1, 2018 AVITA Medical acquired the facility from a Fortune 500 manufacturer that had previously […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-08-23 02:23:402018-09-04 02:28:42AVITA Medical Announces Commencement of Manufacturing of RECELL® Device in Newly Acquired Facility in Preparation for Planned U.S. Launch
Results from two U.S. pivotal trials featured in plenary session at U.S. Defense Department Military Health System Research Symposium Valencia, Calif., USA, and Melbourne, Australia, 22 August 2018 AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that results from two U.S. pivotal clinical trials demonstrating the effectiveness and clinical benefits of the RECELL® Autologous Cell Harvesting […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-08-22 02:19:432018-09-04 02:37:39AVITA Medical Announces Presentation of RECELL® Device Effectiveness and Safety in Treatment of Thermal Burns at Premier U.S. Military Conference
Company update: Global Kinetics Corporation hits significant clinical milestones on its trajectory to revolutionise the treatment of Parkinson’s disease Leading digital health company Global Kinetics’ ground-breaking PKGTM technology recommended by world leading Parkinson’s experts ahead of achieving a key milestone on the path to USA reimbursement PORTSMOUTH, NH USA, LONDON, UK, and MELBOURNE, Australia, August […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-08-21 02:13:322019-02-13 12:19:18The PKG has been recommended by two separate panel experts for routine management of Parkinson’s
21 August 2018 – Asthma and Respiratory Foundation NZ announces today that it has agreed to work with Adherium to improve outcomes for asthma patients, with a special focus on New Zealand children and teenagers, in a collaboration to be known as the Kiwi Kids Program. Adherium is an an award-winning digital health company that improves medication […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-08-20 02:03:442018-09-04 02:06:02Adherium and Asthma and Respiratory Foundation NZ Collaborate to Improve Outcomes for Asthma Patients, with a Special Focus on New Zealand Children
13 Aug 2018 San Mateo, CA – August 13th, 2018: Adherium (ASX: ADR), a leading digital health platform that focuses on improving medication adherence and patient outcomes, today officially launched the Hailie™ solution in the U.S., following its recent Food and Drug Administration (FDA) 510(k) over-the-counter clearance to enable sales direct to consumers. The Hailie solution […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-08-13 05:05:022019-02-13 12:19:51Adherium Launches Hailie™ Solution Direct-to-Consumer in the U.S. for Better Asthma and COPD Management
AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01
/in Armata PharmaceuticalsFDA is in general agreement with the design of two proposed randomized clinical trials of AB-SA01, for Staphylococcus aureus bacteremia and prosthetic joint infections, and no additional preclinical or clinical data are required to proceed with both trials AmpliPhi expects to initiate one of these clinical trials in early 2019 AmpliPhi continues to investigate if […]
AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program
/in Armata Pharmaceuticals21 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have now been treated with AB-SA01 (targeting S. aureus) or AB-PA01 (targeting P. aeruginosa) under AmpliPhi’s expanded access program Over 1,000 doses of bacteriophage product candidates, AB-SA01 or AB-PA01, have been administered as part of the expanded access program since mid-2017 […]
Biopharma Company Arecor raises £6m for revolutionary diabetes treatments
/in Arecor10 September 2018 – Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures. Through the […]
Directorate Change New Chairman Appointment
/in Destiny PharmaDestiny Pharma plc (“Destiny Pharma” or “the Company”) Brighton, United Kingdom – 6 September 2018 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, which address the global problem of antimicrobial resistance (AMR), announces that Sir Nigel Rudd is stepping down as Chairman and a member of […]
Adherium and Vitalus Health Launch Commercial Program to Support Patients with Asthma and COPD
/in Adherium23 Aug 2018 San Mateo, CA – August 23, 2018: Adherium (ASX:ADR) a digital health platform focused on improving medication adherence and patient outcomes, and Vitalus Health, a leading provider of comprehensive health and wellness solutions that focus on pulmonary disease management, today announced a broadened strategic program encompassing Adherium’s Hailie™ solution. With the expansion of its […]
AVITA Medical Announces Commencement of Manufacturing of RECELL® Device in Newly Acquired Facility in Preparation for Planned U.S. Launch
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 23 August 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced the successful completion of multiple production runs for the RECELL Device® within its newly acquired manufacturing facility in Ventura, California. Effective July 1, 2018 AVITA Medical acquired the facility from a Fortune 500 manufacturer that had previously […]
AVITA Medical Announces Presentation of RECELL® Device Effectiveness and Safety in Treatment of Thermal Burns at Premier U.S. Military Conference
/in Avita MedicalResults from two U.S. pivotal trials featured in plenary session at U.S. Defense Department Military Health System Research Symposium Valencia, Calif., USA, and Melbourne, Australia, 22 August 2018 AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that results from two U.S. pivotal clinical trials demonstrating the effectiveness and clinical benefits of the RECELL® Autologous Cell Harvesting […]
The PKG has been recommended by two separate panel experts for routine management of Parkinson’s
/in GKCCompany update: Global Kinetics Corporation hits significant clinical milestones on its trajectory to revolutionise the treatment of Parkinson’s disease Leading digital health company Global Kinetics’ ground-breaking PKGTM technology recommended by world leading Parkinson’s experts ahead of achieving a key milestone on the path to USA reimbursement PORTSMOUTH, NH USA, LONDON, UK, and MELBOURNE, Australia, August […]
Adherium and Asthma and Respiratory Foundation NZ Collaborate to Improve Outcomes for Asthma Patients, with a Special Focus on New Zealand Children
/in Adherium21 August 2018 – Asthma and Respiratory Foundation NZ announces today that it has agreed to work with Adherium to improve outcomes for asthma patients, with a special focus on New Zealand children and teenagers, in a collaboration to be known as the Kiwi Kids Program. Adherium is an an award-winning digital health company that improves medication […]
Adherium Launches Hailie™ Solution Direct-to-Consumer in the U.S. for Better Asthma and COPD Management
/in Adherium13 Aug 2018 San Mateo, CA – August 13th, 2018: Adherium (ASX: ADR), a leading digital health platform that focuses on improving medication adherence and patient outcomes, today officially launched the Hailie™ solution in the U.S., following its recent Food and Drug Administration (FDA) 510(k) over-the-counter clearance to enable sales direct to consumers. The Hailie solution […]